openPR Logo
Press release

Ovarian Cancer - Therapeutics Pipeline Review, Overview, H2 2016

01-03-2017 05:13 PM CET | Health & Medicine

Press release from: MRH

Market Research Hub

Market Research Hub

Albany, New York, January 03, 2017: A recent forecast report focusing on the Ovarian Cancer Market has been added to the wide portfolio of Market Research Hub (MRH). It is entitled as, “Ovarian Cancer - Pipeline Review, H2 2016”. Latest Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer Pipeline Review, H2 2016, provides an overview of the Ovarian Cancer (Oncology) pipeline landscape.

Request for Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=905722

Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, changes in bowel habits, such as constipation, loss of appetite and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ovarian Cancer Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 15, 115, 119, 7, 195, 31 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 11, 11, 34 and 8 molecules, respectively.

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=905722

Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ovarian Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ovarian Cancer (Oncology)

Browse Full Info with TOC: http://www.marketresearchhub.com/report/ovarian-cancer-pipeline-review-h2-2016-report.html

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ovarian Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

90 State Street,
Albany, NY 12207,
United States
Toll Free: 866-997-4948 (US-Canada)
Tel: +1-518-621-2074
Email: press@marketresearchhub.com
Website: http://www.marketresearchhub.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Ovarian Cancer - Therapeutics Pipeline Review, Overview, H2 2016 here

News-ID: 404484 • Views:

More Releases from MRH

Sustainable Building Materials Market COVID-19 Industry Planning Structure - Res …
According to this report, Sustainable Building Materials Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. The report provides an extensive study of the market for the
Global Selenium-rich Agricultural Products Market Insights on Trends,Share, Drivers and Opportunities until the End of 2025 | Global Market leaders - Eankn International, Nanjing Yuanwang Selenium-rich Agricultural Products, Luoyang Fuhai Agricultural Pro
Global Selenium-rich Agricultural Products Market Insights on Trends,Share, Driv …
A newly compiled business intelligent report, titled “Global Selenium-rich Agricultural Products Market Research Report” has been publicized to the vast archive of Market Research Hub (MRH) online repository. The study revolves around the analysis of Selenium-rich Agricultural Products Market , covering key industry developments and market opportunity map during the mentioned forecast period. This report further conveys quantitative & qualitative analysis on the concerned market, providing a 360 view on
Global Swine Feed Premix Market Research Report 2018-2025 | Global Market leaders- Elanco, Cargill, Land O Lakes Feed, Archer Daniels Midland
Global Swine Feed Premix Market Research Report 2018-2025 | Global Market leader …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Global Swine Feed Premix Market Research Report” provides an in-depth analysis of the "Swine Feed Premix Market " with the forecast of market size and growth. The analysis includes addressable market, market by volume, market share by business type and by segment (external and in-house).The research study examines the Swine Feed
New study on global Veterinary Chemistry Analyzers Market Insights & Forecast 2025 | Global Market leaders - Idexx Laboratories, Heska Corporation, Abaxis, Urit Medical Electronic, Randox Laboratories
New study on global Veterinary Chemistry Analyzers Market Insights & Forecast 20 …
An up-to-date research report has been disclosed by Market Research Hub highlighting the title “New study on global Veterinary Chemistry Analyzers Market Research Report” which provides an outlook for current market value as well as the expected growth of "Veterinary Chemistry Analyzers Market " during 2018-2025. The report studies the casing heads market worldwide, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, size, growth, revenue,

All 5 Releases


More Releases for Ovarian

Ovarian Cancer Market Size, Future Trends
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Ovarian Cancer Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion. The impact of manufacturers on the market is significant across various industries, influencing supply chains, consumer choices, and economic growth. Manufacturers are key players in
Polycystic Ovarian Syndrome Treatment Market Report
The findings reviewed by GME stated that the Global Polycystic Ovarian Syndrome Treatment Market will expand with a CAGR value of 5.2 percent from 2021 to 2026. The rising incidence of PCOS increased understanding among a group of patients, and the growing acceptance of standard treatment boosts the PCOS treatment industry growth over the projected timeframe. Furthermore, the research and development of PCOS are predicted to aid in market growth. Browse
Ovarian Cancer Drugs Market Report 2020-2030
Forecasts by Therapeutic Class (PARP, PD-L1, Angiogenesis Inhibitors) Plus Analysis of Leading Companies Download free sample pages: https://www.visiongain.com/report/ovarian-cancer-drugs-market-report-2020-2030/ Ovarian Cancer Drugs Market- our new study reveals trends, R&D progress, and predicted revenues Where the Ovarian Cancer Drugs is market heading? If you are involved in this industry you must read this newly updated report. Visiongain's report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there. Discover
How deadly is Ovarian Cancer?
Ovarian Drugs and Treatment Market describes its growth, size, share, Forecast and trends to 2025 Ovarian cancer is a cancer that forms in or on an ovary. It results in abnormal cells that have the ability to invade or spread to other parts of the body. The global Ovarian Cancer Treatment Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025,
Polycystic Ovarian Syndrome Treatment Market - Regional Analysis
The organic and inorganic strategies by the market players will boost the polycystic ovarian syndrome treatment market. For instance, in 2016, Millendo Therapeutics, Inc., a biopharmaceutical company, entered into an exclusive license agreement with AstraZeneca for the development and commercialization of phase II entered AZD4901, a candidate product for the treatment of polycystic ovarian syndrome. Moreover, in 2017, Astellas Pharma Inc. completed its acquisition of Ogeda SA (formerly Euroscreen S.A.).
Ovarian Cancer - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Ovarian Cancer - Heat Map and Analysis to its growing collection of premium market research reports. Ovarian Cancer (OC) is the fifth most common malignancy diagnosed in women, and the most common gynecological cancer, with an estimated 225,000 new cases diagnosed globally in 2008. Rates are particularly high in developed countries, and especially in Northern Europe. However, substantial improvements in